Skip to main content
. 2011 Jun;55(6):2566–2575. doi: 10.1128/AAC.00032-11

Table 4.

CalcuSyn analysis of PSI-352938 combination studies with ITMN-191, ACH-806, BMS-790052, a benzothiadiazine NNI, PSI-6130, or PSI-7851

Combination and ratioa Combination indexb
 rd
EC50 EC75 EC90
PSI-352938 and ITMN-191
    20:1 0.64 0.68 0.73 0.97
    40:1 0.72 0.73 0.74 0.96
    80:1 0.93 0.83 0.73 0.99
    160:1 1.13 1.12 1.10 0.98
PSI-352938 and ACH-806
    1:5 0.67 0.68 0.69 0.97
    1:2.5 0.63 0.64 0.66 0.95
    1:1.25 0.78 0.76 0.73 0.98
    1:0.63 0.76 0.76 0.76 0.99
PSI-352938 and BMS-790052
    12,500:1 1.01 0.92 0.85 0.97
    25,000:1 1.09 1.11 1.14 0.98
    50,000:1 0.91 0.89 0.88 0.93
    100,000:1 0.92 0.9 0.88 0.93
PSI-352938 and NNIc
    0.8:1 0.60 0.61 0.63 0.99
    1.6:1 0.80 0.70 0.62 0.95
    3.2:1 0.70 0.63 0.58 0.99
    6.4:1 0.77 0.77 0.78 0.92
PSI-352938 and PSI-6130
    1:20 0.51 0.6 0.71 0.94
    1:10 0.51 0.63 0.78 0.98
    1:5 0.62 0.66 0.71 0.98
    1:2.5 0.58 0.62 0.66 0.93
PSI-352938 and PSI-7851
    1:1.25 0.80 0.76 0.71 0.99
    1:0.63 1.06 1.03 1.00 0.98
    1:0.31 1.02 0.91 0.81 0.99
    1:0.16 1.17 1.15 1.13 0.98
a

Compounds were combined in a checkerboard format, where 10 different concentrations of PSI-352938 were added horizontally and 8 different concentrations of another HCV inhibitor were added vertically to a 96-well plate. For each ratio indicated, at least six different combinations of PSI-352938 and the other anti-HCV compound were included for calculation of the combination index value.

b

Combination index values at 50%, 75%, and 90% inhibition were calculated using the CalcuSyn program.

c

The NS5B NNI used here was a benzothiadiazine-derived compound targeting an allosteric site within the palm domain of NS5B.

d

The r value is the linear correlation coefficient that indicates the goodness of fit for the data.